Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AGI-1067: Additional Phase III data

Additional data from the double-blind, international Phase III ARISE trial in 6,127 patients showed that AGI-1067 significantly lowered baseline HbA1c levels

Read the full 215 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE